GlobalData analysed all terminated trials within the Clinical Trials Database and found the top five therapy areas by trial count to be Oncology, Central Nervous System, Cardiovascular, Infectious Disease, and Metabolic Disorders, in descending order.
Go deeper with GlobalData
The largest phase of termination occurred in Phase II in all therapeutic areas (Figure 1), as well as across all terminated trials. Overall, Phase II accounted for 50% of all terminated trials and Oncology was the only therapy area that exceeded this, where 65% of all Phase II trials were terminated.
The biggest reason for trial discontinuation in Oncology was “low accrual rate,” at 35% of all terminated trials with reasons given. This was followed by “unspecified” at 25%, “other” at 16%, “lack of efficacy” at 10%, and “adverse events” at 6% rounding out the top five reasons.
Image: Top five therapy areas in terminated trials. Credit: GlobalData.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
Related Company Profiles
Oncology, Ltd.